Lemsip Max Honey & Ginger Flavour oral powder sachets

Pays: Royaume-Uni

Langue: anglais

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingrédients actifs:

Paracetamol; Phenylephrine hydrochloride

Disponible depuis:

Reckitt Benckiser Healthcare (UK) Ltd

Code ATC:

N02BE51

DCI (Dénomination commune internationale):

Paracetamol; Phenylephrine hydrochloride

Dosage:

1gram ; 12.2mg

forme pharmaceutique:

Powder for oral suspension

Mode d'administration:

Oral

classe:

No Controlled Drug Status

Type d'ordonnance:

Valid as a prescribable product

Descriptif du produit:

BNF: 04070100; GTIN: 5000158069862

Résumé des caractéristiques du produit

OBJECT 1
LEMSIP MAX HONEY & GINGER FLAVOUR POWDER
FOR ORAL SOLUTION
Summary of Product Characteristics Updated 07-Sep-2016 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Lemsip Max Honey & Ginger Flavour Powder for Oral Solution.
2. Qualitative and quantitative composition
_Active Ingredients_
_Mg/Sachet_
_Specification_
Paracetamol
1000.00
Ph Eur
Phenylephrine hydrochloride*
12.20
Ph Eur
* Equivalent to phenylephrine (base) 10.0 mg.
3. Pharmaceutical form
A white to off-white powder for oral solution
4. Clinical particulars
4.1 Therapeutic indications
For relief of the symptoms of colds and influenza, including the
relief of aches and pains, sore throat,
headache, nasal congestion and lowering of temperature.
4.2 Posology and method of administration
Oral administration after dissolution in water.
Adults and children over 12: One sachet dissolved by stirring in hot
water and sweetened to taste.
The dose may be repeated in 4-6 hours.
No more than four doses should be taken in 24 hours.
Not to be given to children under 12 without medical advice.
There is no indication that dosage need be modified in the elderly.
4.3 Contraindications
• Hypersensitivity to paracetamol, phenylephrine or any other
ingredient.
• Severe coronary heart disease and cardiovascular disorders.
• Hypertension.
• Hyperthyroidism.
• Contraindicated in patients currently receiving or within two
weeks of stopping therapy with
monoamine oxidase inhibitors (see section 4.5).
4.4 Special warnings and precautions for use
Use with caution in patients with Raynaud's phenomenon or diabetes
mellitus.
Care is advised in the administration of paracetamol to patients with
severe renal or severe hepatic
impairment. The hazard of overdose is greater in those with
non-cirrhotic alcoholic liver disease. Patients
should be advised not to take other paracetamol -containing products
concurrently.
Each sachet contains approximately 2.0 g of carbohydrate. Due to its
aspartame content this product
should not be given to patients